|1.||Béhé, Martin: 2 articles (03/2011 - 10/2005)|
|2.||Krenning, Eric P: 2 articles (04/2004 - 03/2003)|
|3.||Valkema, Roelf: 2 articles (04/2004 - 03/2003)|
|4.||Mansi, Rosalba: 1 article (06/2015)|
|5.||Sollner Dolenc, Marija: 1 article (06/2015)|
|6.||Kolenc Peitl, Petra: 1 article (06/2015)|
|7.||Reubi, Jean Claude: 1 article (06/2015)|
|8.||Braun, Friederike: 1 article (06/2015)|
|9.||Waser, Beatrice: 1 article (06/2015)|
|10.||Tamma, MariaLuisa: 1 article (06/2015)|
03/01/2011 - "For in vivo studies, tumor cells were implanted into mice, and DY-minigastrin in presence or absence of nonlabeled minigastrin (control of signaling specificity) was applied intravenously. "
11/03/2014 - "The minigastrin analogue PP-F11 has previously been shown to be a promising peptide for imaging of CCK-2 receptor positive tumors and was therefore further evaluated. "
03/01/2013 - "Minigastrin peptide analogues (MG-CL1-4) were synthesised and labeled with 111-In radioisotope under different sets of conditions for imaging CCk-2 receptor bearing tumors. "
03/01/2011 - "In vivo NIRF whole-body animal imaging, again, demonstrated a clear depiction of HT-29 tumors, which was reversed by blocking with nonlabeled minigastrin. "
04/01/2007 - "Minigastrin analogs containing a pentaglutamate sequence showed the highest tumor uptake but very high renal retention. "
|2.||Melanoma (Melanoma, Malignant)
05/01/2004 - "Radiochemical yields (RCYs) of N-(4-[(18)F]fluorobenzylidene)oxime ([(18)F]FBOA) formation with various aminooxy-modified peptides such as minigastrin, RGD, and octreotate analogs were investigated as a function of reaction time and temperature, peptide concentration, and pH. Biodistribution studies were performed with an [(18)F]FBOA-RGD dimer ((c(RGDfE)HEG)(2)-K-Dpr-[(18)F]FBOA, 60 and 120 min after injection) and a gylcosylated [(18)F]FB-Tyr(3)-octreotate (Gluc-S-Dpr([(18)F]FBOA)TOCA), 10 and 60 min after injection) using M21 and M21L human melanoma and AR42J rat pancreatic tumor-bearing nude mice, respectively. "
|3.||Thyroid Neoplasms (Thyroid Cancer)
03/01/2003 - "For PRRT of CCK-B receptor-positive tumours, such as medullary thyroid carcinoma, radiolabelled minigastrin analogues are currently being successfully applied. "
04/01/2004 - "For PRRT of CCK-B receptor-positive tumors, such as medullary thyroid carcinoma, radiolabeled minigastrin analogues currently are being successfully applied. "
02/01/1980 - "Three synthetic preparations of big gastrin (G-34), little gastrin (G-17) and minigastrin (G-14) have been compared with regard to gastric acid stimulatory potency, rate of disappearance and the relation between acid secretion and the change in serum immunoreactive gastrin in gastric fistula and Heidenhain pouch dogs. "
|1.||Cholecystokinin B Receptor
|6.||Peptide Receptors (Peptide Receptor)
|7.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|8.||Folic Acid (Vitamin M)